Some years ago, a young man came to me for his cancer. He was prescribed some herbs and he did not. He preferred instead to go for chemotherapy. Not long after his wife came to my house in the middle of the night and asked for help. She said that following chemotherapy, her husband has red blood cells is drastically reduced. The doctor gave him an injection to stimulate blood values. He suffered a blood clot in his leg and had to undergo an emergencyoperation. She wanted to help him with herbs. But it was not to be, her husband died shortly after.
In the early days of my practice, I did not document that patients have come to see me. Yes, I have only vague memories of some outstanding issues. This was a good thing that I remember, where a young professional. When he had cancer, I could see the pain and despair in the face of his young wife.
This case would not have shown and are inif not press for a series of articles I just read on the net for erythropoiesis-stimulating agents (ESA). The ESA is often used for anemia, that is fewer than normal red blood cells to be treated. Examples of such drugs are Procrit, Epogen and Aranesp. These are synthetic, genetically engineered version of a glycoprotein known as natural erythroprotein. The U.S. FDA has approved the use of ESAs to treat anemia in patients with chronic renal failure and cancer patients afterchemotherapy had lowered their blood counts. Patients in Malaysia, each injection takes a good amount of clean money.
According to Alison Tonka, associate editor of the British Medical Journal (BMJ), "thousands of patients around the world are based on synthetic ETA of cancer to alleviate the anemia associated with chronic kidney disease and chemotherapy." Two reports in the BMJ had these titles: "Drug safety erythopoitin anemia should be reviewed" and "FDA calls for warninganemia drugs amid reports of incentives to doctors. "The main message of these articles is that more patients treated with ESA treatment to the deceased, rather than longer term or be helped. That is, the risk of death increased ESA. Studies have also shown that a dose higher than ESA indicated a heart attack can cause an increased risk of blood clots, stroke e. In patients with head and neck cancer, high doses of ESAs promote tumor growth.
In November 2006, Februaryand in March 2007, the FDA has put out security alerts to inform the public about these security issues. The network, I learned the following:
1. ETA can be severe and life-threatening side effects.
2. A greater number of deaths occurred in patients treated with these injections to stimulate blood counts compared to patients not chemotherapy.
3. ETA lead to an increased rate of tumor growth in patients who had radiotherapy to their head and neck cancer and chemotherapyfor metastatic breast cancer.
4. ETA lead to an increased risk of death and proliferation of blood clots, stroke, heart failure and heart attacks in patients with chronic renal failure.
All users of this drug in the blood-count of improvement should be said to have an increased risk of death and serious cardiovascular complications including stroke, heart attack, blood clots in the heart, lungs, brain and major blood vessels. People with chronic renal failureETA is not given to epileptic seizures and hypertensive encephalopathy, which is swelling of the brain caused by high blood pressure.
Now I know why this young man has met his untimely death after chemotherapy, plus a shot of erythropoiesis-stimulating agents (ESA), the doctor has given him. Goethe, a German philosopher, once wrote: "There is nothing more frightening than active ignorance."
See Also : Wet Ear Smog Pollution
No comments:
Post a Comment